CERTARA INC (CERT)

Notable Two Hundred Day Moving Average Cross - CERT

Certara Launches Cloud Platform to Further Unify its End-to-End Scientific Software Platform

Certara to Report First Quarter 2024 Financial Results on May 7th, 2024 and Participate in the BofA Securities Healthcare Conference

Certara to Report First Quarter 2024 Financial Results on May 7th, 2024 and Participate in the BofA Securities Healthcare Conference

PRINCETON, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release...

Certara Reports Fourth Quarter 2023 Financial Results

Provides Full Year 2024 Financial Guidance

Certara Reports Fourth Quarter 2023 Financial Results

Provides Full Year 2024 Financial Guidance...

Notable earnings after Thursday's close

Major earnings expected after the bell on Thursday include:Zscaler (ZS)Hewlett Packard Enterprise Company (HPE)Dell Technologies (DELL)Autodesk (ADSK)Veeva...

CERT Crosses Above Key Moving Average Level

Certara to Report Fourth Quarter and Full Year 2023 Financial Results on February 29th, 2024 and Participate in the Barclays 26th Annual Global Healthcare Conference

Certara to Report Fourth Quarter and Full Year 2023 Financial Results on February 29th, 2024 and Participate in the Barclays 26th Annual Global Healthcare Conference

PRINCETON, N.J., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release...

CERT Makes Bullish Cross Above Critical Moving Average

Certara acquires Applied BioMath (NASDAQ:CERT)

Certara acquires Applied BioMath, expanding its biosimulation portfolio to industrialize new drug discovery and development support.

Certara Acquires Applied BioMath Expanding Its Biosimulation Portfolio to Industrialize New Capabilities for Optimal Dosing for Novel Therapies

Combined organization establishes the life sciences industry’s largest quantitative systems pharmacology (QSP) center of excellence contributing to faster and more effective medicine development.

Certara Acquires Applied BioMath Expanding Its Biosimulation Portfolio to Industrialize New Capabilities for Optimal Dosing for Novel Therapies

Combined Certara-Applied Biomath organization establishes the life sciences industry’s largest quantitative systems pharmacology center....

KeyBanc sees opportunity in tech-enabled drug discovery stocks (NASDAQ:ABCL)

KeyBanc has initiated coverage of the tech-enabled drug discovery subsector, citing increasing demand for products that can help lower drug development costs. Read more here.

Certara introduces Simcyp™ Biopharmaceutics software to increase efficiency of novel and generic drug formulation & development

Simcyp Biopharmaceutics helps drug developers replace costly clinical bioequivalence studies and optimize formulations for complex therapies

Certara introduces Simcyp™ Biopharmaceutics software to increase efficiency of novel and generic drug formulation & development

Certara's Simcyp™ Biopharmaceutics software helps biopharmaceutic, formulation & CMC scientists formulate complex new and generic drugs faster and...

Commit To Buy Certara At $12.50, Earn 14.4% Annualized Using Options

Certara Non-GAAP EPS of $0.11, revenue of $85.6M (NASDAQ:CERT)

Certara press release (NASDAQ:CERT): Q3 Non-GAAP EPS of $0.11.Revenue of $85.6M (+1.1% Y/Y).Expects Full year 2023 revenue to be in the range of $345...

Certara Reports Third Quarter 2023 Financial Results

Reiterates Full Year 2023 Financial Guidance

Certara Reports Third Quarter 2023 Financial Results

Reiterates Full Year 2023 Financial Guidance...

Relative Strength Alert For Certara

Certara to Report Third Quarter 2023 Financial Results on November 8th, 2023, and participate in the Stephens Annual Investment Conference

Certara to Report Third Quarter 2023 Financial Results on November 8th, 2023, and participate in the Stephens Annual Investment Conference

PRINCETON, N.J, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release...

Certara Enters Oversold Territory (CERT)

Certara Announces 300th Regulatory Submission Milestone Using its Technology-enabled Services and Software

Dedicated team of global regulatory experts delivers submissions in increasingly shorter timelines

Certara Announces 300th Regulatory Submission Milestone Using its Technology-enabled Services and Software

Dedicated team of global regulatory experts delivers submissions in increasingly shorter timelines...

Certara to Participate in Upcoming Investor Conferences

Certara to Participate in Upcoming Investor Conferences

PRINCETON, N.J., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that Company...

Certara's software platform Simcyp group awarded two new grants from US FDA (NASDAQ:CERT)

Certara (CERT) Tuesday announced that its software platform Simcyp group was awarded two new grants from the U.S

Certara Simcyp™ Group Awarded Two New Grants from US FDA

Programs focus on use of physiologically-based pharmacokinetic (PBPK) modeling for demonstrating virtual bioequivalence and predicting drug absorption of topical formulations

Certara Simcyp™ Group Awarded Two New Grants from US FDA

Programs focus on use of physiologically-based pharmacokinetic (PBPK) modeling for demonstrating virtual bioequivalence and predicting drug absorption of...

Certara stock downgraded at Jefferies on growth headwinds

Certara (CERT) traded lower Tuesday after Jefferies downgraded citing a lower likelihood of growth for the health tech company in 2024. Read more here.